https://www.selleckchem.com/products/ibmx.html
2% and 1.5%, according to age group (65 or 65 to 74 years of age), and number of non-sex comorbidities of the CHA DS -VASc score (0 or 1). Interestingly, in patients with EHRA Type 2 VHD65 years of age with 0 or 1 comorbidity, the risk was 1.5% (95% confidence interval 0.7% to 2.8%) and 1.5% (95% confidence interval 0.6% to 3.4%) at 1 year after the atrial fibrillation diagnosis. These observations suggest that in atrial fibrillation patients with EHRA Type 2 VHD, who are not currently recommended oral anticoagulant therapy accordi
Like
Comment
Share
